Zurich Insurance Group Ltd FI Makes New $6.58 Million Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Zurich Insurance Group Ltd FI bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 27,977 shares of the biopharmaceutical company's stock, valued at approximately $6,583,000.

A number of other institutional investors have also modified their holdings of ALNY. Jennison Associates LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth approximately $61,160,000. Strategic Financial Concepts LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $41,529,000. Truist Financial Corp boosted its holdings in shares of Alnylam Pharmaceuticals by 136.6% in the 4th quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock valued at $1,035,000 after buying an additional 2,539 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its position in shares of Alnylam Pharmaceuticals by 3.0% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company's stock worth $67,464,000 after buying an additional 8,462 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in shares of Alnylam Pharmaceuticals by 13.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company's stock worth $4,687,000 after acquiring an additional 2,285 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY traded up $0.96 during midday trading on Monday, reaching $289.96. 757,018 shares of the company's stock traded hands, compared to its average volume of 918,662. The company has a market cap of $37.81 billion, a P/E ratio of -133.62 and a beta of 0.17. The company has a fifty day simple moving average of $258.36 and a two-hundred day simple moving average of $254.19. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. Alnylam Pharmaceuticals, Inc. has a 1 year low of $146.79 and a 1 year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The firm had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. During the same quarter last year, the business posted ($0.16) EPS. The firm's revenue for the quarter was up 20.2% on a year-over-year basis. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ALNY has been the subject of several analyst reports. Needham & Company LLC reiterated a "buy" rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 9th. HC Wainwright reiterated a "buy" rating and issued a $500.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. Canaccord Genuity Group raised their price target on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a report on Friday, March 21st. Citigroup upped their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a report on Friday, March 21st. Finally, Stifel Nicolaus increased their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research report on Monday, March 31st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have issued a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $319.17.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.